VANCOUVER, Dec. 20, 2018 /CNW/ - INVICTUS MD
STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX:
IVITF; FRA: 8IS1) is pleased to announce that its
wholly-owned licensed producer, Acreage Pharms Ltd. ("Acreage
Pharms"), has entered into a five-year supply and distribution
agreement with Deutsche Medizinalcannabis GmbH ("Deutsche
Medizinalcannabis") for a total of 10,000 kgs of dried cannabis
flower. Deutsche Medizinalcannabis is an importer and distributor
of medical cannabis in Germany
with a vast distribution network and direct access to 20,000
pharmacies and a clear focus on product marketing and professional
education (see press releases dated June 19,
2018 and September 24, 2018,
for further details).
"We are thrilled to partner with Deutsche Medizinalcannabis to
supply medical cannabis to the German market. At present, there is
insufficient supply to meet patient demand in Germany and this is a great opportunity to
expand our distribution and sales beyond Canada," said George
E. Kveton, CEO of Invictus. "Both companies share the same
beliefs regarding the importance of product quality and it has been
a pleasure working with Deutsche Medizinalcannabis as we prepare
our Phase 3 facility at Acreage Pharms to be EU-GMP compliant."
"Highest medical quality and reliable constant supply is what
German patients deserve and what both, Invictus and Deutsche
Medizinalcannabis, stand for. It has been a terrific experience to
work with Invictus in achieving EU-GMP compliance for their Acreage
Pharms facility." said Cornelius
Maurer, Co-Founder and CEO of Deutsche Medizinalcannabis.
"Invictus' supply will ease the product shortage in German
pharmacies and lay the foundation for Deutsche Medizinalcannabis to
become Germany's most reliable
wholesaler of medical cannabis products. We are excited to further
develop our international network of EU-GMP certified suppliers
through this partnership."
Prior to any shipment of dried cannabis flower to the German
market, the Company must first obtain an export permit from Health
Canada as well as a Good Manufacturing Practice ("EU-GMP")
certification, in accordance with the rules governing medicinal
products in the European Union. The EU-GMP certification is a
requirement to distribute medical cannabis to Germany and across the European Union.
Deutsche Medizinalcannabis must in turn obtain an import
permit.
For more information, please visit www.invictus-md.com and
www.deutschemedizinalcannabis.de
On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director
Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363
About Deutsche Medizinalcannabis
Deutsche Medizinalcannabis is a German cannabis company founded
to bring the highest quality medical cannabis products to
Germany and Europe. The company is driven by patient needs
and works closely with doctors and pharmacists to secure and
maintain the quality of all imported product. At the same time, its
cooperation with licensed producers from around the world provides
the basis to ensure a steady and reliable supply of medical
cannabis. Their experienced management team has been involved with
the fast-growing German and European markets of medical cannabis
since the earliest stages. They bring together entrepreneurial
success, medical and legal expertise as well as sound knowledge of
EU-GMP regulations. This unique track record, together with a
distribution network that reaches 20,000 pharmacies in Germany will allow Deutsche Medizinalcannabis
to become the leading importer and wholesaler of medical cannabis
products in Germany.
For more information visit www.deutschemedizinalcannabis.de
About Invictus
Invictus is a global cannabis company offering a selection of
products under a wide range of brands. Our integrated sales
approach is defined by five pillars of distribution including
medical, adult-use, international, Licensed Producer to Licensed
Producer and retail stores.
Invictus has partnered with business leaders to convey our
corporate vision, including KISS music legend and business mogul
Gene Simmons as our Chief Evangelist
Officer. To meet growing demand, Invictus is expanding its
cultivation footprint, with three cannabis production facilities
licensed under the Cannabis Act and Cannabis Regulations in
Canada. To accommodate
international sales, Invictus' wholly-owned subsidiary, Acreage
Pharms Ltd. ("Acreage Pharms"), has designed and is currently
building its Phase 3 purpose-built cultivation facility to be
European Union Good Manufacturing Practices ("EU-GMP") compliant.
The Company is targeting up to 50 per cent of production to medical
cannabis. To ensure consistency in quality and supply, Invictus
maintains all aspects of the growing process through its
subsidiary, Future Harvest Development Ltd. ("Future Harvest"), a
high-quality fertilizer and nutrients manufacturer. Invictus drives
sustainable long-term shareholder value through a diversified
product portfolio with over 70 Health Canada approved strains and a
multifaceted distribution strategy including medical, adult-use,
international, Licensed Producer to Licensed Producer and retail
stores. For more information visit www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance. Generally, forward-looking
statements and information can be identified by the use of
forward-looking terminology such as "intends" or "anticipates", or
variations of such words and phrases or statements that certain
actions, events or results "may", "could", "should", "would" or
"occur". Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that Invictus will reach full production capacity on the
timeline anticipated by the Company. These forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information. Although
management of the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements or forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements and forward-looking
information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company
does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invictus-signs-five-year-10-000-kg-supply-agreement-with-deutsche-medizinalcannabis-in-germany-300769563.html
SOURCE Invictus MD Strategies